Intellia Therapeutics has received orphan drug status from the FDA for its drug NTLA-5001. The drug is for acute myeloid leukemia. This status provides the company with tax benefits for qualified clinical testing of the drug, a prescription drug tax exemption and seven years of marketing exclusivity following FDA approval.
Intellia Therapeutics has received orphan drug status from the FDA for its drug NTLA-5001. The drug is for acute myeloid leukemia. This status provides the company with tax benefits for qualified clinical testing of the drug, a prescription drug tax exemption and seven years of marketing exclusivity following FDA approval. 
ir.intelliatx.com
English (US) 